Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J7RK
|
|||
| Former ID |
DAP000245
|
|||
| Drug Name |
Dobutamine
|
|||
| Synonyms |
Dobutamina; Dobutaminum; Dobutamine Hcl; Dobutamine [USAN]; Dobutamine hydrobromide; LY 81929; Lilly 81929; DL-dobutamine; Dobutamina [INN-Spanish]; Dobutamine Hcl in Dextrose 5%; Dobutamine(usp); Dobutaminum [INN-Latin]; Rac-dobutamine; Racemic-Dobutamine; Dobutamine (USP/INN); Dobutamine [USAN:BAN:INN]; Dobutamine Tartrate (1:1), (S-(R*,R*))-Isomer; (+-)-4-(2-((3-(p-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol; 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine; 4-(2-{[3-(4-hydroxyphenyl)-1-methylpropyl]amino}ethyl)benzene-1,2-diol; 4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol; 4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Heart failure [ICD-11: BD10-BD13] | Approved | [1], [2] | |
| Therapeutic Class |
Cardiotonic Agents
|
|||
| Company |
Ben Venue Laboratories
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H23NO3
|
|||
| Canonical SMILES |
CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O
|
|||
| InChI |
1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3
|
|||
| InChIKey |
JRWZLRBJNMZMFE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 34368-04-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9181, 5680486, 7979113, 8174668, 11466380, 11467500, 11486100, 14825296, 17397963, 26751752, 34678180, 46505241, 47434355, 47879635, 47953969, 48104696, 48253451, 48415917, 49698448, 50064706, 50104446, 53788487, 57311932, 78153929, 85209842, 85788850, 90341592, 92308881, 99313634, 103241510, 104171143, 104324888, 117616952, 117646595, 124749655, 124879838, 124879839, 124879840, 124879841, 124879842, 128318768, 134337559, 134998867, 135650199, 137241858, 142059874, 144203677, 160964182, 163882666, 170465050
|
|||
| ChEBI ID |
CHEBI:4670
|
|||
| ADReCS Drug ID | BADD_D00697 ; BADD_D00698 | |||
| SuperDrug ATC ID |
C01CA07
|
|||
| SuperDrug CAS ID |
cas=034368042
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-1 (ADRB1) | Target Info | Agonist | [3], [4] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Gap junction | ||||
| Salivary secretion | ||||
| Dilated cardiomyopathy | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta1 adrenergic receptor signaling pathway | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 535). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074086. | |||
| REF 3 | Beta-adrenoceptor alterations coupled with secretory response and experimental periodontitis in rat submandibular glands. Arch Oral Biol. 2008 Jun;53(6):509-16. | |||
| REF 4 | Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect. Circulation. 1994 Jun;89(6):2760-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.